文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

醋酸林格液与生理盐水在脓毒症中的比较:一项随机对照试验

ACETATE RINGER'S SOLUTION VERSUS NORMAL SALINE SOLUTION IN SEPSIS: A RANDOMIZED, CONTROLLED TRIAL.
PubMed 文献 · Shock · 2024-02-01
一句话结论单中心RCT显示脓毒症患者用醋酸林格液与生理盐水28天内主要不良肾脏事件无统计学差异(23.3% vs 20.0%,OR 1.2,P=0.69)。

该单中心前瞻性开放标签平行对照试验纳入143例成人脓毒症患者,随机接受醋酸林格液(RAS)或生理盐水(NSS)静脉输注5天,每组中位输液量2 L。主要终点28天内主要不良肾脏事件(MAKE28)在RAS组与NSS组无统计学差异(23.3% vs 20.0%;OR 1.2 [0.6-2.2];P=0.69)。事后分析中RAS-only组与NSS-only组MAKE28亦无统计学差异(23.3% vs 27.3%;OR 0.82 [0.35-1.94];P=0.65),NSS-only组有创机械通气天数更长,血清氯有蓄积趋势。作者指出入ICU前大量液体复苏和载体生理盐水可能缩小了平衡盐溶液与生理盐水之间的差异,尚不明确。

要点

  • 脓毒症患者接受RAS或NSS 5天,MAKE28发生率RAS组23.3% vs NSS组20.0%,OR 1.2(0.6-2.2),P=0.69,无统计学差异。
  • 事后分析RAS-only组MAKE28 23.3% vs NSS-only组27.3%,OR 0.82(0.35-1.94),P=0.65,无统计学差异。
  • NSS-only组有创机械通气天数更长,血清氯有蓄积趋势。
  • 39.3%的患者入ICU前已接受500 mL(500-1,000 mL)平衡盐溶液,作者认为可能缩小了两组差异。

适用人群与场景

  • 成人(>18岁)脓毒症患者,单中心ICU场景。

处置流程与药物剂量

  • RAS组或NSS组静脉输注5天,每组中位输液量2 L。
  • 39.3%的患者入ICU前已接受500 mL(500-1,000 mL)平衡盐溶液。

研究设计与关键结果

  • 单中心前瞻性开放标签平行对照试验,筛查255例,纳入143例(RAS组51.0%,NSS组49.0%)。
  • 主要终点MAKE28:RAS组23.3% vs NSS组20.0%,OR 1.2(0.6-2.2),P=0.69。
  • 事后分析MAKE28:RAS-only组23.3% vs NSS-only组27.3%,OR 0.82(0.35-1.94),P=0.65。
  • NSS-only组有创机械通气天数更长,血清氯有蓄积趋势。
  • 30天/90天死亡率、急性肾损伤、高氯血症等次要终点在RAS与NSS组间无统计学显著差异。

证据类型、等级与局限

  • 证据类型:单中心前瞻性开放标签平行对照随机对照试验。
  • 局限:作者指出入ICU前大量液体复苏和载体生理盐水可能缩小了平衡盐溶液与生理盐水之间的差异,尚不明确。

对床旁实践的改变

  • 作者认为,由于入ICU前大量液体复苏和载体生理盐水可能缩小差异,RAS与NSS对脓毒症患者MAKE28及次要结局的影响尚不明确。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: Normal saline solution (NSS) and Ringer's acetate solution (RAS) are commonly given to critically ill patients as a fundamental fluid therapy. However, the effect of RAS and NSS on sepsis patient outcomes remains unknown. Methods: We conducted a single-center prospective open-label parallel controlled trial to enroll adult patients (>18 years old) diagnosed with sepsis. Participants received either RAS or NSS for intravenous infusion for 5 days. The primary outcome was the incidence of major adverse kidney events within 28 days (MAKE28). Secondary outcomes included 30-/90-day mortality, acute kidney injury, and hyperchloremia. The patients were then reclassified as NSS-only, RAS-only, and RAS + NSS groups according to the type of fluid they had received before enrollment. Thereafter, a secondary post hoc analysis was performed. Results: Two hundred fifty-five septic patients were screened, and 143 patients (51.0% in RAS group and 49.0% in NSS group) were enrolled in the study. Each group received a median of 2 L of fluid administration during five interventional days. Of the patients, 39.3% had received 500 mL (500-1,000 mL) of balanced salt solutions (BSSs) before intensive care unit (ICU) admission. There was no statistical difference among the RAS and NSS group on the primary outcome MAKE28 in the initial analysis (23.3% vs. 20.0%; OR, 1.2 [0.6 to 2.2]; P = 0.69). MAKE28 was observed in 23.3% of RAS-only versus 27.3% of NSS-only group patients (0.82 [0.35-1.94], P = 0.65) in the secondary post hoc analysis. The patients in the NSS-only group had a longer invasive mechanical ventilation days and a trend toward the accumulation of serum chloride. Conclusion: This study observed no statistically significant difference on MAKE28 and secondary outcomes among sepsis patients receiving RAS and NSS. However, it is unclear whether the large amount of fluid resuscitation before ICU admission and carrier NSS narrowed the difference between BSSs and NSSs.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Zhang J, Liu F, Wu Z, et al. ACETATE RINGER'S SOLUTION VERSUS NORMAL SALINE SOLUTION IN SEPSIS: A RANDOMIZED, CONTROLLED TRIAL. Shock. 2024. PMID: 38369528. doi:10.1097/SHK.0000000000002324

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。